OR WAIT 15 SECS
The studies will soon be published, reports the ingredient’s supplier Natreon Inc. and its exclusive North American distributor NutraGenesis.
The Sensoril ashwagandha brand has been studied in five new double-blind, placebo-controlled human clinical trials, which will soon be published, reports the ingredient’s supplier Natreon Inc. (New Brunswick, NJ) and Sensoril’s exclusive North American distributor NutraGenesis (Brattleboro, VT).
The first study assessed Sensoril’s ability to enhance memory and mental cognition in patients experiencing short-term memory and focus issues. The second study looked at Sensoril for Generalized Anxiety Disorder, whose symptoms include excessive worrying and the ability to relax.
The third study examined Sensoril’s effects on endothelial function, both when taken alone and in combination with Capros, a patented Indian gooseberry extract, compared to a statin drug. Subjects were measured for lipid profile, inflammation, glutathione increase, nitric oxide increase, and blood sugar balance. Finally, the last two studies looked at cardiovascular changes in healthy subjects under cold stress and mental stress conditions.